Teva Post Lupin Deal To Launch Austedo Generic Rival In 2033

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Teva can rest easy knowing that it does have a long runway free of generics—at least from two major challengers—as it focuses on the tardive dyskinesia drug Austedo for growth. Teva has settled its patent infringement action with Aurobindo Pharma over the latter’s application to commercialise a generic version of Austedo. Aurobindo has a licence to start selling its generic in the United States in April 2033 or early under specific conditions, according to the agreement.

Teva’s most valuable medicine is undoubtedly Austedo. Last year, the med raked in $802 million, a 26% increase over 2020. Another generic player has been held off until 2033 by the Israeli company. Teva and Lupin reached an agreement last month to let the latter sell its generic form of Austedo in April 2033. Last July, Teva filed lawsuits against Lupin and Aurobindo, alleging violation of numerous patents it controls.

Teva claims that Austedo is so far the only FDA-approved medication for chorea linked with Huntington’s disease and tardive dyskinesia. The medication was first approved by the FDA in 2017. According to a statement, Teva feels that the Aurobindo settlement is a reflection of the integrity of its property rights.

Latest stories

Related stories

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back